No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRXP240517C2500
- 0.65
- +0.01+1.56%
15min DelayClose May 10 15:55 ET
0.65High0.65Low
0.65Open0.64Pre Close2 Volume36 Open Interest2.50Strike Price130.00Turnover284.68%IV5.26%PremiumMay 17, 2024Expiry Date0.54Intrinsic Value100Multiplier4DDays to Expiry0.11Time Value100Contract SizeAmericanOptions Type0.7744Delta0.2949Gamma4.34Leverage Ratio-0.0316Theta0.0002Rho3.36Eff Leverage0.0011Vega
Intraday
- 5D
- 1D
News
Express News | NRX Pharmaceuticals Inc: Eyes First Commercial Revenue in 2024
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
RADNOR, Pa., May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will rele
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data
By Chris Wack NRx Pharmaceuticals shares were up 38% to $2.90 after the company said it saw a statistically significant safety advantage of NRX-101 compared to the standard of care comparator in its
12 Health Care Stocks Moving In Monday's Intraday Session
GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc
Comments
Encouraged by these results, NRx Pharmaceuticals plans to seek accelerated FDA approval for NRX-101 for patients with bipolar depression at risk of akathisia.
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...
Read more